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Adam Olesen, PharmD; Kristen Wendell, PharmD, BCGP
Health & Services
Background
• The Program of All-Inclusive Care of the Elderly 
(PACE) is a nation-wide medical care model that 
offers comprehensive community-based care for 
medically frail participants eligible for nursing home 
level of care. On national average, a PACE participant 
has six chronic conditions and is taking nine 
maintenance medications.1
• A minority of PACE programs (approximately five of 
126 programs nationwide) embed geriatric clinical 
specialist pharmacists within the PACE care team. 
• This study was performed within a PACE network 
associated with a tertiary care center that assigns 
geriatric clinical pharmacists to patient care teams 
with a participant ratio of approximately 300 for each 
pharmacist FTE.
• Pharmacist duties include patient assessments, 
disease state management, and medication review at
enrollment and at subsequent transitions of care.
• Upon enrollment with the PACE facility, every 
participant’s medication profile is reviewed by a 
clinical pharmacist, who then works with both the 
participant and PCP to address drug-related issues. 
• Pharmacist-led interventions are presumed to improve 
patient care and reduce cost. However, there is not
currently a process in place to objectively capture and 
evaluate pharmacist work.
• Previous studies have demonstrated clinical and cost 
saving benefits of pharmacist involvement in 
transitions of care of medically complex patients.2
Purpose
To quantify and characterize the number and type of 
interventions and recommendations made by 
pharmacists at PACE program enrollment
Methodology
Study Design
Retrospective analysis of pharmacist interventions and 
recommendations completed at time of enrollment for all 
new participants with enrollment dates from November 
1, 2019 to January 31, 2020
Primary Endpoint
Composite analysis of: 
• Number of interventions completed upon enrollment
• Types of interventions
Secondary Endpoints
• Percentage of recommendations presented by 
pharmacists that are implemented at enrollment and 
within two months following enrollment. Progression 
towards a recommendation was counted as accepted
• Whether the intervention pertains to a medication on 
the 2019 Beers List
• Number of recommendations of which the primary 
goal was to reduce polypharmacy(defined as unused 
medications on an enrollee's medication profile)
Inclusion Criteria
All new PACE enrollees within the study period
Exclusion Criteria
Disenrolled from PACE program during the study period 
Data Collection
Prior to initiation of study, pharmacists were trained on 
intervention documentation system within electronic 
health record (EPIC i-Vents)
Discussion
• Pharmacists were able to implement 68% of their 
interventions on date of enrollment. Interventions most 
commonly made prior to establishing a patient-provider 
relationship include discontinuing medications without 
indication, formulary interchanges, and addressing 
polypharmacy. 
• Of the 168 interventions not accepted at enrollment, 47% 
were implemented within two months. This resulted in a 
cumulative total of 83% of pharmacist recommendations 
being implemented within two months of enrollment. The 
most common of these were therapeutic optimization, 
recommended screenings, recommended drug 
discontinuations, and recommended labs to obtain. 
• There were 192 drugs for 52 patients were discontinued due 
to polypharmacy. These were defined as unused drugs that 
were possessed by the patient or on their prescription list. 
This indicates that many geriatric patients have many unused 
or unnecessary drugs on their medication profile that can lead 
to complications in their care. 
• Pharmacists recommended the discontinuation of 74 drugs 
due to lack of indication. These are medications the patients 
were still taking. Discontinuing these medications is an 
effective way to reduce pill burden and ADRs in geriatric 
patients. 
• Therapy optimization (drug change, addition, discontinuation, 
or dose adjustment) comprised 45% of pharmacist 
interventions. This demonstrates that a large amount of the 
interventions performed by pharmacists includes clinical 
decision making that may best benefit the patient. A total of 
76% of these recommendations were accepted across the 
study period, indicating that provider’s clinical thought 
processes may be in agreement with that of the pharmacists.
• Investigators found minimal need to adjust i-Vent coding or to 
retrain pharmacists on appropriate use. This suggests that 
pharmacist training on use of the system has been adequate.
Limitations
• While coding required minimal adjustments, it is still possible 
that a pharmacist coded an intervention as one type i-Vent 
while it was more applicable as another. 
• If an intervention may have applied to multiple i-Vents, 
pharmacists were required to identify a primary reason for 
their recommendation. This subjective decision-making was 
pharmacist-specific and does risk coding bias. 
Conclusions
• Patients enrolling in PACE programs are often medically 
complex and stand to benefit from medication review by a 
pharmacist.
• Pharmacists make quantifiable interventions that contribute to 
transition into a Program of All-include Care for the Elderly. 
• The most common interventions completed at enrollment 
were therapy optimization, drug discontinuation, and 
formulary interchanges. 
• The recommendations most accepted at two-month follow-up 
were related to therapy optimization.
Next Steps
• An evaluation of the financial impact these interventions 
have on the PACE program.
• Analysis of the interventions and recommendations a 
pharmacist makes every month on participants that are 
already enrolled with the PACE program. 
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Intervention Number of 
interventions
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Interventions 
accepted at 
enrollment, n 
(%)
Interventions 
accepted between
enrollment date 
and two months, n 
(% of remaining)
Total interventions 
implemented at 2 
months, n (%)
Therapy Optimization
Drug Change
Drug Discontinuation
Drug Addition
Renal Dose Adjust
238
88
86
61
3
145
48 (55)
62 (72)
33 (54)
2 (67)
37
16 (40)
12 (50)
8 (29)
0 (0)
181 (76)
64 (73)
74 (86)
41 (67)
2 (67)
Formulary Interchange 71 62 (87) 9 (13) 71 (100)
Polypharmacy Reduction 52 51 (98) 1 (2) 52 (100)
Lab Recommendations 47 34 (72) 10 (21) 44 (94)
Beers List Medication 41 29 (71) 2 (5) 31 (76)
Screening 
Recommendations
33 5 (15) 14 (42) 19 (58)
Related to anticoagulation 13 9 (69) 4 (31) 13 (100)
Patient's Own Medication 12 11 (92) 0 (0) 11 (92)
Minor ADR addressed 8 6 (75) 1 (13) 7 (88)
Specialist Referral 4 0 (0) 2 (50) 2 (50)
Prior Authorization 3 3 (100) -- 3 (100)
Fall Prevention 2 1 (50) 0 1 (50)
Interventions documented for 108 enrollees 
across 3 months
n=524
Implemented at 
enrollment
n=356 (68%)
Implemented within 
two months
n=79 (15%)
Awaiting Provider 
Approval
n=89 (17%)
